AMERICAN SOCIETY OF CLINICAL ONCOLOGY

🇺🇸United States
Ownership
-
Established
1964-01-01
Employees
-
Market Cap
-
Website
http://www.asco.org
news.med.miami.edu
·

Five Advances Transforming Breast Cancer Care and Prevention

Sylvester Comprehensive Cancer Center pioneers five advances in breast cancer care: pill-based prevention, TAPUR study precision medicine, circadian alignment for treatment-related fatigue, SLYMPHA surgical procedure for lymphedema, and comprehensive lymphedema treatment.
newswise.com
·

UCSF Radiation Oncologist Honored for Prostate Cancer Care and Research

Mack Roach, III, MD, FASTRO, receives ASTRO's 2024 Gold Medal Award for significant contributions to radiation oncology, particularly in prostate cancer treatment. Roach pioneered techniques like 3D conformal radiation therapy and IMRT, developed predictive models, and led phase III trials. His work on health disparities and community service further underscores his impact.
cancernetwork.com
·

Novel PET Imaging Agent Earns Fast Track Status for PSMA+ Prostate Cancer

64Cu-SAR-bisPSMA received FDA fast track designation for PET imaging of PSMA-positive prostate cancer lesions. Clinical trials showed 100% and 85.7% detection rates, higher uptake than 68Ga-PSMA-11, and minimal adverse effects, positioning it as a potential best-in-class diagnostic.
urologytimes.com
·

Phase 3 trial progresses of padeliporfin VTP therapy in upper tract urothelial carcinoma

The phase 3 ENLIGHTED trial has reached 50% enrollment, with interim data showing 77% complete response in low-grade UTUC patients treated with padeliporfin VTP therapy. The trial aims to enroll 100 patients across 29 sites, with full enrollment expected by Q1 2025. The therapy involves intravenous padeliporfin and laser fiber illumination, with common AEs being mild and resolving quickly. The study's primary objective is to assess efficacy and durability, with secondary objectives focusing on safety and tolerability.
pharmabiz.com
·

Johnson & Johnson announces updated results from phase 1b RedirecTT-1 study of Talvey

Johnson & Johnson's RedirecTT-1 study shows high response rates and durable responses with Talvey and Tecvayli bispecific antibody combination in relapsed or refractory multiple myeloma patients, including those with extramedullary disease, with a consistent safety profile. The overall response rate was 79.5%, with a complete response or better rate of 52.3%.
nature.com
·

Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic

LEANORA (NCT04657679) was a prospective, observational, multicenter cohort study assessing ribociclib's pharmacokinetics and pharmacogenomics in HR+/HER2− metastatic breast cancer patients. Enrolled women self-identified as NHW or African American/Black, with ovarian suppression for premenopausal patients. The study initially planned two cohorts but closed the NHW cohort due to low enrollment. Pharmacokinetic and pharmacogenetic testing, including CYP3A5 genotyping, was conducted. Primary endpoints were ribociclib AUCtau and CYP3A5 PM vs. IM/NM, with secondary endpoints including pharmacokinetic properties and adverse events. Statistical analysis included Wilcoxon rank-sum test and exploratory candidate gene analysis for ribociclib pharmacokinetics.
biospace.com
·

ImPact Biotech Announces 50% Enrollment in Phase 3 ENLIGHTED Clinical Trial of ...

ImPact Biotech announces 50% enrollment in Phase 3 ENLIGHTED trial for Padeliporfin VTP in low-grade UTUC, anticipating full enrollment by Q1 2025. Interim results show 77% CR rate, with additional data expected in Q4 2024.
ajmc.com
·

Talquetamab Combo Updates Show Durable Responses in Heavily Pretreated Patients

Talquetamab, a bispecific GPRC5D-directed CD3 T-cell engager, demonstrated durable responses in multiple myeloma patients with 4-5 prior therapies in TRIMM-2 and RedirecTT trials. Updated phase 1b results showed an 81.8% ORR and 15.5-month median PFS in the TRIMM-2 triplet arm, and a 79.5% ORR at 18 months in the RedirecTT-1 dual bispecific arm. Both combinations showed robust durability and efficacy, even in high-risk patients with extramedullary disease.
© Copyright 2024. All Rights Reserved by MedPath